

Special Issue

Helicobacter pylori Virulence Factors, Antibiotic Susceptibility and Persistent Infection

Message from the Guest Editors

The first edition of the Special Issue, entitled “*Helicobacter pylori* Virulence Factors and Antibiotic Susceptibility”, was published in 2020. It was a successful collection comprising nine excellent papers. This encouraged us to launch a second edition on the same topic. As a continuation of the first Special Issue, this second edition focuses on state-of-the-art research regarding *H. pylori* virulence factors together with their effect on gastric tissue and correlation with several symptoms related to *H. pylori* infection and the relationship with oral/gastric microbiome and chemosusceptibility. The aim is to better understand the complex relationship between virulence and antibiotic resistance, as well as to investigate the persistent phenotypical forms of *H. pylori* strains and a possible correlation with virulence factors. The results of this research may help to develop therapeutical strategies with new combinations of anti-virulence strategies that will allow us to provide more specific and directed drug treatments.

Guest Editors

Dr. Mara Di Giulio
Dr. Teresa Fasciana
Dr. Chiara Pagliuca

Deadline for manuscript submissions

31 January 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/207503

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)